Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) shares saw unusually-high trading volume on Monday . Approximately 182,960 shares traded hands during mid-day trading, an increase of 98% from the previous session’s volume of 92,516 shares.The stock last traded at $2.04 and had previously closed at $2.14.

CNAT has been the subject of several recent research reports. FBR & Co reaffirmed a “buy” rating on shares of Conatus Pharmaceuticals in a report on Monday, April 18th. Brean Capital reissued a “buy” rating and set a $7.00 target price (down previously from $13.00) on shares of Conatus Pharmaceuticals in a research note on Monday, May 9th. Finally, Roth Capital initiated coverage on Conatus Pharmaceuticals in a research note on Friday, July 1st. They set a “buy” rating for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company’s stock. Conatus Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $9.66.

The firm’s 50 day moving average price is $2.18 and its 200 day moving average price is $2.21. The stock’s market capitalization is $42.99 million.

Conatus Pharmaceuticals (NASDAQ:CNAT) last announced its quarterly earnings results on Wednesday, August 3rd. The biotechnology company reported ($0.30) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.38) by $0.08. During the same period in the previous year, the business posted ($0.31) EPS. Equities analysts predict that Conatus Pharmaceuticals Inc. will post ($1.39) EPS for the current fiscal year.

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.